Home > Browse Research > Life Sciences > Pharmaceuticals > Diseases & Conditions > Cancer Treatment

Cancer Treatment: market research reports

Worldwide cancer affects more than 10 million people each year and the incidence of cancer is expected to increase by 2.4% annually to reach 14 million per year by 2020. Cancer is the second most common death in the industrialized world.

Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States.

Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.

With the growing incidence of cancer, a growing and aging world population and significant medical advances, there will continue to be phenomenal growth in the market for cancer diagnosis and treatment products.

Cancer Treatment market research reports and industry analysis

The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives 5/8/2013 \| published by: Kalorama Information ... selection, therapy monitoring and early detection of cancer recurrence. The market for cancer testing are comprehensively covered in Kalorama Information's Worldwide Market for Cancer Diagnostics, 5th. Edition. This report, authored by Kalorama Diagnostic Analyst Shara ... \| read more...	$4,500.00
US Personalized Cancer Genome Sequencing Marketrncos 5/1/2013 \| published by: RNCOS ... the most attractive sectors due to its inherent capability of high revenue generation and efficiency in terms of personalized treatment. In order to properly analyze the virtues and significance of the US personalized cancer Whole-Genome ... \| read more...	$1,200.00
Lymphoma Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ... \| read more...	$2,000.00
Oropharyngeal Cancer – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... for Oropharyngeal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oropharyngeal Cancer. Oropharyngeal Cancer - Pipeline Review, Half Year ... \| read more...	$2,000.00
Metastatic Ovarian Cancer – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... therapeutic development for Metastatic Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer. Metastatic Ovarian Cancer ... \| read more...	$2,000.00
Cancer Pain Global Clinical Trials Review, H1, 2013 4/30/2013 \| published by: GlobalData ... information and data relating to the clinical trials on Cancer Pain. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ... \| read more...	$2,500.00
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also ... \| read more...	$2,000.00
2013 Analysis of the PT and APTT Point-of-Care Testing Market: US, Germany, Spain,-Physician Offices, Emergency Rooms, Operating Suites, ICIs/CUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers 4/29/2013 \| published by: Venture Planning Group ... landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effective business, R&D and marketing strategies for the global POC coagulation market. Rationale The growing economic pressures on ... \| read more...	$4,500.00
Bladder Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... treated early, the 5 year survival rate is 94%. There are today 98 companies plus partners developing 111 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number ... \| read more...	$3,746.25
Brain Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are ... \| read more...	$5,621.25
Cancer Stem Cells Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today ... \| read more...	$5,621.25
Colorectal Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years. There are today 299 companies ... \| read more...	$5,621.25
ErbB Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces ... \| read more...	$5,621.25
Head and Neck Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... accumulated number of ceased drugs over the last years amount to another 42 drugs. Head And Neck Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ... \| read more...	$5,621.25
HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... (O(2)) and nutrient availability. The hypoxia-inducible factors (HIFs) are a common link between adaptation to low O(2), changes in cancer metabolism, and malignant progression. This report focusses around the cancer drugs targeting the hypoxia-inducible factor ... \| read more...	$5,621.25
Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. There are today 347 companies plus partners developing 517 cytokine-cytokine receptor interaction ... \| read more...	$5,621.25
Interfering With the ECM-Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... tissue and organ morphogenesis and in the maintenance of cell and tissue structure and function. There are today 48 companies plus partners developing 37 targeting ECM-receptor interaction drugs in 116 developmental projects in cancer. In ... \| read more...	$1,871.25
Lung Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe ... \| read more...	$5,621.25
NOD-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... more than 20 members in mammals and plays a pivotal role in the recognition of intracellular ligands. There are today 81 companies plus partners developing 67 NOD-like receptor signaling pathway targeting drugs in 186 developmental ... \| read more...	$3,746.25
Ovarian Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... an important secondary indication for existing and pipeline drugs. There are today 220 companies plus partners developing 306 drugs targeting ovarian cancer in development. In addition, there are 8 suspended drugs and the accumulated number ... \| read more...	$5,621.25
PI3K-Akt Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... translation, proliferation, growth, and survival. There are today 439 companies plus partners developing 763 PI3K-Akt signaling pathway targeting drugs in 2339 developmental projects in cancer. In addition, there are 12 suspended drugs and the accumulated ... \| read more...	$7,496.25
Prostate Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... been eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca`s Casodex (bicalutamide) have also seen a significant proportion of physicians switching to alternatives. Establishing the optimal timing of antihormonal therapy ... \| read more...	$5,621.25
Renal Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... existing cytokine therapy being less than 20% (RCC) in this patient cohort.The identification of biomarkers is set to revolutionize patient staging and prognosis by individualizing patient treatments and creating novel drug targets. There are today ... \| read more...	$5,621.25
RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... a result of intracellular viral replication is recognized by a family of cytosolic RNA helicases termed RIG-I-like receptors (RLRs). There are today 53 companies plus partners developing 33 RIG-I-like receptor signaling pathway targeting drugs in ... \| read more...	$1,871.25
Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional ... \| read more...	$5,621.25

< prev 1 2 3 4 5 6 7 8 9 10 next >